Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;1(3):209-214.
doi: 10.1007/s40139-013-0018-7.

Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts

Affiliations

Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts

Xiao Liu et al. Curr Pathobiol Rep. 2013 Sep.

Abstract

Many studies have demonstrated that hepatic fibrosis is reversible. Regression of liver fibrosis is associated with resorption of fibrous scar and disappearance of collagen producing myofibroblasts. The fate of these myofibroblasts has been recently revealed: Some myofibroblasts undergo senescence and apoptose during reversal of fibrosis, while other myofibroblasts revert to a quiescent-like phenotype. Inactivation of myofibroblasts is a newly described phenomenon1 which now requires mechanistic investigation. Understanding of the mechanism of HSC inactivation upon cessation of fibrogenic stimuli may identify new approaches to revert already existing aHSCs/myofibroblasts into a quiescent-like state. This review summarizes the research on the inactivation of hepatic myofibroblasts.

Keywords: Collagen; HSCs; Hepatic fibrosis; Hepatic stellate cells; Inactivation of myofibroblasts; Pathobiology; Reversibility of liver fibrosis.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethics Guidelines

Conflict of Interest

Xiao Liu and Jun Xu declare that they have no conflict of interest.

David A. Brenner holds a patent for inducing inactivation of fibrogenic myofibroblasts. Tatiana Kisseleva holds a patent for inducing inactivation of fibrogenic myofibroblasts, and has received research support from National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (R56 DK088837-01A10.

Figures

Figure 1
Figure 1
Study design to determine the cell fate of aHSCs during regression of CCl4-induced liver fibrosis. Adapted from Kisseleva and Brenner [8]. A. Cre-loxP based genetic labeling marks the fate of Col-α1(I) expressing aHSCs/ myofibroblasts in Col-α1(I)Cre-YFP mice generated by crossing Col-α1(I)Cre and Rosa26f/f-YFP mice. B. Col-α1(I)Cre-YFP mice were subjected to CCl4-induced liver injury (1.5 months), then recuperated upon cessation of injuring agent (for 1 month). Mice were sacrificed and livers were analyzed for the presence of Vitamin A+ YFP+ and Vitamin A+ YFP HSCs. C. CCl4 induces qHSC activation into aHSCs/myofibroblasts in Col-α1(I)Cre-YFP mice. After CCl4 withdrawal, some aHSCs apoptose while some inactivate (YFP+ iHSCs number <100% of aHSCs).
Figure 2
Figure 2
Differential expression of cell surface antigens by different HSC types. Based on the whole genome microarray, we have identified mRNAs that are specifically upregulated in qHSCs: Nr1d2; Adipor1 - Adiponectin receptor 1, Adfp - Adipose differentiation-related protein, GFAP - Glial fibrillary acidic protein, Dbp - D site of albumin promoter (albumin D-box) binding protein, Prei4; Foxj1 - Forkhead box protein J1. The mRNAs were specifically upregulated in aHSCs: αSMA - Alpha-actin-2 (also known as actin, aortic smooth muscle or alpha smooth muscle actin); Col1 1; TIMP-1 - tissue inhibitor of metalloproteinase 1, Crlf1 – cytokine receptor-like factor 1; IL1r1 - Interleukin 1 receptor, type I (IL1R1, CD121a), Itga5 - Integrin alpha-5; Spp1 - secreted phosphoprotein 1 (Osteopontin (OPN), also known as bone sialoprotein I (BSP-1 or BNSP), early T-lymphocyte activation, ETA-1); Lox - lysyl oxidase; LoxL2 - lysyl oxidase-like 1; IL-17ra - Interleukin 17 receptor A; Fosl1 - fos-like antigen 1; Folr1 - folate receptor 1. The following mRNA s were upregulated in iHSCs: Rnd1 - Rho family GTPase 1; Csf1R - colony stimulating factor 1 receptor; IL7R - interleukin-7 receptor; Cntfr - ciliary neurotrophic factor receptor; Csf2rb - colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage); Cx3cr1 - CX3C chemokine receptor 1 (fractalkine receptor or G-protein coupled receptor 13, GPR13); Ly86 - lymphocyte antigen 86 (CD180/MD-1), Cxcl2 - chemokine (C-X-C motif) ligand 2 (Cxcl2); Fos - FBJ osteosarcoma oncogene; Egr1 - epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans); Spic - Spi-C transcription factor (Spi-1/PU.1 related); Atf3 - activating transcription factor 3. Several mRNAs were upregulated both in qHSCs and iHSCs: Mrc1 - mannose receptor 1, Agtr1a - Angiotensin II receptor, type 1 (or AT1 receptor); Calcrl - calcitonin receptor-like; Grap - GRB2-related adapter protein, Ngfr - The Low-Affinity Nerve Growth Factor Receptor (also called the LNGFR or p75 neurotrophin receptor); Insig1 - insulin induced gene 1; PPARγ-peroxisome proliferator activated receptor gamma; CD36; IL-10RA - interleukin 10 receptor, alpha; Foxo1 - forkhead box O1; Tal1 - helix-loop-helix protein; Bambi - BMP and activin membrane-bound inhibitor, homolog (Xenopus laevis).

References

    1. Kisseleva T, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A. 2012;109:9448–9453. This research article, along with the one by Troeger [30], demonstrated for the first time that aHSCs can inactivate, initiating a new area of research and providing new direction for anti-fibrotic therapy. - PMC - PubMed
    1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–218. - PMC - PubMed
    1. Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. Journal of gastroenterology and hepatology. 2006;21 (Suppl 3):S84–87. - PubMed
    1. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112:1776–1784. - PMC - PubMed
    1. Gomperts BN, Strieter RM. Fibrocytes in lung disease. Journal of leukocyte biology. 2007;82:449–456. - PubMed